WuXi PharmaTech (NYSE: WX) Welcomes Mr. Wu Bangguo in Its Preclinical Testing Facility
Jan 20, 2010
Mr. Wu Bangguo, Chairman of the Standing Committee of the National People's Congress and member of the Standing Committee of the Politburo of the Communist Party of China (CPC), visited WuXi PharmaTech's preclinical testing facility in SuZhou on January 16. Mr. Wu is China's chief legislator. He was accompanied by Mr. Liang Baohua, Chairman of the CPC Committee of Jiangsu Province.
Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, introduced Mr. Wu to WuXi PharmaTech and accompanied him on a tour of the facility. Mr. Wu spoke with WuXi scientists and learned of the company's many contributions to pharmaceutical research and development.
"Developing people is the key to improving China's industrial capabilities and nurturing knowledge-based economic growth," Mr. Wu said. "We must always remember that human resources are of paramount importance." Mr. Wu praised the accomplishments of WuXi PharmaTech's scientists and encouraged them to continuously innovate and lead the development of China's life science industry.
"Mr. Wu Bangguo's visit is a great honor and inspiration to us all," commented Dr. Li. "WuXi PharmaTech will continue to foster its culture of scientific innovation, operational excellence, and dedicated service to the world's leading pharmaceutical, biotech, and medical-device companies."
About WuXi AppTec and WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, we provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners to improve the success of research and shorten the time of development cost effectively in discovering and developing drugs and medical devices. Please visit: http://www.wuxiapptec.com.